NEWS
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Ovid Therapeutics and Graviton Bioscience announced positive Phase 1 trial results for their OV888/GV101 capsule, a potential first-in-class therapy for cerebral cavernous malformations (CCM). The trial met its primary objective by demonstrating a favorable safety and tolerability profile, with no serious adverse events reported. Secondary endpoints showed target pharmacokinetic profiles were achieved, supporting once-daily dosing. The capsule was biologically active, producing dose-dependent pharmacodynamic effects. A Phase 2 study is planned for the second half of 2024. The findings indicate OV888/GV101 could be the first oral treatment for CCM, aiming to restore brain endothelial cell function, reduce inflammation, and prevent fibrosis.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2875Followers
108Following
30KVisitors
Follow